Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine

@article{Vosjan2010ConjugationAR,
  title={Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine},
  author={Maria Vosjan and Lars R. Perk and Gerard W. M. Visser and Marianne Budde and Paul Jurek and Garry E Kiefer and Guus A.M.S. van Dongen},
  journal={Nature Protocols},
  year={2010},
  volume={5},
  pages={739-743}
}
The positron emitter zirconium-89 (89Zr) has very attractive properties for positron emission tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. This protocol describes the step-by-step procedure for the facile radiolabeling of mAbs or other proteins with 89Zr using p-isothiocyanatobenzyl-desferrioxamine (Df–Bz–NCS). First, Df–Bz–NCS is coupled to the lysine–NH2 groups of a mAb at pH 9.0 (pre-modification), followed by purification using gel filtration. Next, the… Expand
Photochemical Conjugation and One-Pot Radiolabelling of Antibodies for Immuno-PET.
TLDR
A photoradiochemical approach that uses fast, chemoselective, light-induced protein modification under mild conditions with novel metal-ion-binding chelates derivatised with aryl azide (ArN3 ) groups is developed and experiments show that one-pot photochemical conjugation and radiolabelling of formulated mAbs can be achieved in <20 min. Expand
A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET.
TLDR
It is suggested that synthesizing trastuzumab immunoconjugates bearing 1-3 DFOs per Ab (T5 and T10) combined with radiolabeling performed in low reaction volumes using chelexed-PBS without a radioprotectant provided radioimmunconjugates having high Am; As and highly preserved immunoreactive fractions with excellent tumor uptake. Expand
Light-activated protein-conjugation and 89Zr-radiolabelling with water-soluble desferrioxamine derivatives.
TLDR
Two photoactivatable DFO-derivatives functionalised with an aryl azide (ArN3) for use in light-activated conjugation and radiosynthesis of 89Zr-mAbs are introduced and can be readily synthesised in accordance with Good Laboratory Practice (GLP), which will facilitate clinical trials with photoradiolabelled 89 Zr- mAbs. Expand
New Bifunctional Chelators Incorporating Dibromomaleimide Groups for Radiolabeling of Antibodies with Positron Emission Tomography Imaging Radioisotopes
TLDR
New bifunctional chelators of sar and dfo have been functionalized with dibromomaleimides (dbm), that enable site-specific and highly stable attachment of molecular cargoes to reduced, solvent-accessible, interstrand native disulfide groups. Expand
Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging
TLDR
A procedure for dual labeling of mAbs with IRDye800CW and 89Zr in a current good manufacturing practice (cGMP)-compliant way to avoid unnecessary radiation exposure to personnel. Expand
The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.
TLDR
In this protocol, the prostate-specific membrane antigen targeting antibody J591 will be used as a model system to illustrate the bioconjugation of the bifunctional chelator DFO-isothiocyanate to an antibody, the radiosynthesis and purification of a 89Zr-DFO-mAb radioimmunoconjugate, and in vivo PET imaging in a murine model of cancer. Expand
Novel Bifunctional Cyclic Chelator for 89Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates
TLDR
Findings indicate that FSC is a highly promising chelator for the development of 89Zr-based PET imaging agents. Expand
Light-induced synthesis of protein conjugates and its application in photoradiosynthesis of 89Zr-radiolabeled monoclonal antibodies
TLDR
This protocol describes a step-by-step procedure for the light-induced functionalization of proteins with compounds bearing the photochemically active aryl azide group and can be easily adapted to prepare other radiolabeled proteins, ADCs or fluorescently tagged proteins by using drug molecules or fluorophores functionalized with photoactive moieties. Expand
Use of [ superscript 18 ] F 2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer
We generated F-labeled antibody fragments for positron emission tomography (PET) imaging using a sortase-mediated reaction to install a trans-cyclooctenefunctionalized short peptide onto proteins ofExpand
Radiolabeling and Imaging of Adoptively Transferred Immune Cells by Positron Emission Tomography.
  • A. Najjar
  • Chemistry, Medicine
  • Methods in molecular biology
  • 2020
TLDR
A two-step radiometal labeling procedure utilizing the bifunctional siderophore p-isothiocyanatobenzyl-desferrioxamine (DFO-Bz-NCS) that chelates 89Zr with high affinity and binds covalently to primary amines of cell-surface proteins via its isothiOCyanate moiety is described. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
TLDR
Methods were developed for improved purification of the long-lived positron emitter (89)Zr and the production of optimal-quality mAb-(89) Zr conjugates, which demonstrated selective tumor targeting and stability and appeared to be superior to the reference conjugate. Expand
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
TLDR
The similar biodistribution and the favorable imaging characteristics make (89)Zr a promising candidate for use as a positron-emitting surrogate for (90)Y, and an excellent correlation was found between image-derived tumor uptake data and gamma-counter values of excised tumors. Expand
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
TLDR
Preliminary data justify the further development of antibody-PET with (89)Zr-labeled MAbs for scouting of therapeutic doses of (90)Y-labeling MAbs and the potential of the positron emitters zirconium-89 and iodine-124 for this approach, as these radionuclides have a relatively long half-life that matches with the kinetics of MAbs in vivo. Expand
PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
TLDR
Scintigraphic tumor imaging using chimeric moAb G250 labeled with 89Zr (immuno-PET) or 111In (RIS), and [18F]FDG-(PET) was explored in rats with s.c. renal cell carcinoma (RCC) tumors, and relatively small tumors could be visualized, even without a dedicated PET camera for small animals. Expand
Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients
TLDR
Evaluated diagnostic imaging performance of immuno-PET with 89Zr-labeled-chimeric mAb (cmAb) U36 in patients with squamous cell carcinoma of the head and neck, who were at high risk of having neck lymph node metastases performed at least as good as CT/MRI for detection of HNSCC lymph nodes metastases. Expand
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
PurposeTo evaluate whether 89Zr can be used as a PET surrogate label for quantification of 90Y-ibritumomab tiuxetan (90Y-Zevalin) biodistribution and dosimetry before myeloablativeExpand
Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
TLDR
89Zr immuno-PET can be safely used to quantitatively assess biodistribution, uptake, organ residence times, and radiation dose, justifying its further clinical exploitation in the detection of tumors and planning of mAb-based therapy. Expand
Immuno-PET: a navigator in monoclonal antibody development and applications.
TLDR
In this review, recent technical advances leading to a jump ahead in mAb imaging are discussed and immuno-PET might play an important future role in cancer staging, in the improvement and tailoring of therapy with existing mAbs, and in the efficient development of novel mAbs. Expand
Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.
TLDR
The opportunities and challenges of radioimmunoimaging with select longer-lived positron-emitting radionuclides such as (124)I, (89)Zr, and (86)Y with respect toRadionuclide production, ease of radiolabeling intact antibodies, imaging characteristics, radiation dosimetry, and clinical translation potential are examined. Expand
The promise of immuno-PET in radioimmunotherapy.
TLDR
General information about PET, PET systems, and quantification is provided in this review and the requirements for an appropriate positron emitter and characteristics of the most attractive candidate emitters for immuno-PET are discussed. Expand
...
1
2
3
...